# A Study of REGEND003 on Patients With Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD)

> **NCT07275788** · PHASE1 · RECRUITING · sponsor: **Regend Therapeutics** · enrollment: 15 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD)

## Interventions

- **BIOLOGICAL:** REGEND003
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07275788
- **Lead sponsor:** Regend Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-08
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07275788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07275788, "A Study of REGEND003 on Patients With Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD)". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT07275788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*